Literature DB >> 14978767

Protection and selection for gene therapy in the hematopoietic system.

Michael D Milsom1, Leslie J Fairbairn.   

Abstract

Hematopoietic stem cell gene therapy is potentially curative for a number of inherited and acquired disorders. However, poor gene transfer and expression in repopulating hematopoietic stem cells attenuate this potential. Here we review potential means of conferring a selective advantage to hematopoietic stem cells and their progeny, and discuss the issues that surround the use of selective advantages in vivo. Copyright 2004 John Wiley & Sons, Ltd.

Mesh：

Substances：

Year:  2004        PMID： 14978767     DOI： 10.1002/jgm.533

Source DB:  PubMed          Journal:  J Gene Med        ISSN： 1099-498X            Impact factor:   4.565


  6 in total

1.  Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Authors:  Ute Modlich; Jens Bohne; Manfred Schmidt; Christof von Kalle; Sabine Knöss; Axel Schambach; Christopher Baum
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

Review 2.  Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Christopher Baum
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 3.  DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy.

Authors:  Julie L Tubbs; Anthony E Pegg; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 4.  Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.

Authors:  Michael D Milsom; David A Williams
Journal:  DNA Repair (Amst)       Date:  2007-05-07

5.  Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.

Authors:  Mahesh Jonnalagadda; Christine E Brown; Wen-Chung Chang; Julie R Ostberg; Stephen J Forman; Michael C Jensen
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

6.  Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Authors:  M Jonnalagadda; C E Brown; W C Chang; J R Ostberg; S J Forman; M C Jensen
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.